Oncology · Ovarian CancerTrial Updateclinicalmid-term

CRLX101 and Paclitaxel Combination Study in Ovarian Cancer Initiated by NewLink Genetics

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:31:45 AM

Assessment confidence: 52% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of CRLX101 in combination with paclitaxel is significant as it could enhance NewLink Genetics' position in the competitive ovarian cancer treatment landscape. Positive outcomes may lead to expanded treatment options and increased market share for NewLink's portfolio. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 23 ranked evidence items (3 high-relevance).

Strategic Assessment

Positive results could enhance NewLink's portfolio and support further development of CRLX101 in combination therapies. The strongest clinical anchor is A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ClinicalTrials.gov), entity match (newlink genetics). In Oncology · Ovarian Cancer, 3 regulatory and 4 competitive items passed relevance filtering for NewLink Genetics.

Competitive Pressure

The most relevant competitive pressure comes from Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer (Humanexa Signals) — moderate corpus alignment. Secondary pressure from Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer. This study could provide insights into the efficacy and safety of CRLX101, potentially positioning NewLink Genetics favorably in the ovarian cancer treatment landscape.

Regulatory Outlook

Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Moderate corpus alignment. Successful trial results could facilitate regulatory approvals for CRLX101 in combination therapies, impacting its market entry and labeling.

Key Risks

Elevated medium regulatory exposure for NewLink Genetics could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on NewLink Genetics through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If the trial demonstrates efficacy, it could lead to increased adoption of CRLX101, potentially boosting NewLink's revenue and market presence in oncology.
Lead sponsor: NewLink Genetics Corporation. The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.
Upside for NewLink Genetics may improve if A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for NewLink Genetics may improve if A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ClinicalTrials.gov) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor for results on maximum tolerated doses and pharmacokinetic interactions between CRLX101 and paclitaxel.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ClinicalTrials.govhigh relevance
Entity match (newlink genetics)
FDA document
View source
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Folate receptor-targeted PEGylated PLGA nanoparticles for the site-specific delivery of hesperidin in epithelial ovarian cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Polyploid giant cancer cells: the hidden players in ovarian cancer progression and prognosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

NewLink Genetics
CRLX101
Paclitaxel
Ovarian Cancer Market

Commercial impact

medium

If the trial demonstrates efficacy, it could lead to increased adoption of CRLX101, potentially boosting NewLink's revenue and market presence in oncology.

Regulatory impact

medium

Successful trial results could facilitate regulatory approvals for CRLX101 in combination therapies, impacting its market entry and labeling.

What to watch

Monitor for results on maximum tolerated doses and pharmacokinetic interactions between CRLX101 and paclitaxel.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.